VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex Inc. (NASDAQ: VERX) has unveiled a new survey showcasing the critical role of automation and digital transformation in ...

Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Morgan Stanley analyst Chris Quintero raised the firm’s price target on Vertex (VERX) to $62 from $50 and keeps an Overweight rating on the shares. The firm has greater conviction in Vertex being a ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Vertex Inc. (NASDAQ:VERX) ("Vertex” or the "Company”), a global provider of tax technology solutions, announced a new survey ...

Vertex achieved its highest level of activity for fiscal 2024 in the current quarter, reporting an adjusted EBITDA (1) of $11.9 million, surpassing the previous company record by $1.0 million. This ...